Genedx Holdings Corp. · NASDAQ:WGS
Genedx — Q2 2023 Earnings Presentation
6 slides from Genedx's earnings presentation, Aug 8, 2023
Slide 1: One Test: Miss Less. Discover More. 2Q 2023 Earnings Presentation
One Test: Miss Less. Discover More. GeneDx (Nasdaq: WGS) 2Q 2023 Earnings Presentation August 8, 2023
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for
Slide 3: Our mission: deliver personalized and actionable health insights
Our mission: deliver personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery.
Slide 4: 2Q 2023 and Recent Highlights
2Q 2023 and Recent Highlights Accelerated whole exome and genome test volume growth by 56% year-over-year Total revenue of $48M in Q2 is inclusive of 36% growth of exome and genome test revenue Expanded gross margins and operating expense rationalization resulting in continued cash burn reduction of
Slide 5: Test Mix Continues to Shift with Growth in Pro Forma Volume and Revenue Generated from WES/WGS
Test Mix Continues to Shift with Growth in Pro Forma Volume and Revenue Generated from WES/WGS Q2 2023 Volume Mix Q2 2023 Revenue Mix 1 54,928 total tests $45.2M revenue 11,855 Q2 WES/WGS tests $28.7M Q2 WES/WGS revenue +56% YoY and +36% QoQ +36% YoY and +28% QoQ WES/WGS tests grew to 22% of tests 3
Slide 6: 2023 Guidance
2023 Guidance Revenues between $205-220 million for full year 2023 Expanded adjusted gross margin profile 2023 and beyond Expects to use $70 to $85 million of net cash for the second half of 2023, inclusive of servicing obligations of the previously exited business activities Expected to turn profit